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SUMMARY
This study compared high dose ranitidine versus low dose omeprazole with antibiotics for the
eradication ofHpylori. 80 patients (mean age 48 years, range 18-75) who had H pylori infection
were randomised in an investigator-blind manner to either a two-week regime ofomeprazole 20
mg daily, amoxycillin 500 mg tid and metronidazole 400 mg tid (OAM), or ranitidine 600 mg bd,
amoxycillin 500 mg tid and metronidazole 400 mg tid (RAM), or omeprazole 20 mg daily and
clarithromycin 500 mg tid (OC), or omeprazole 20 mg daily and placebo (OP). H pylori was
eradicated in 6 of19 patients in the OAM group (32%); 8 of 18 in the RAM group (44%), 4 of15
in the OC group (27%); none of 18 in the OP group (0%). [<PO.005 for OAM, RAM, OC vs OP;
P=N. S. between OAM, RAM, OC]. Overall metronidazole resistance was unexpectedly high at
58%. Eradication rates in metronidazole sensitive patients were 71% (5/7) and 100% (3/3) for
OAMand RAMrespectively. Inconclusion, Hpylori eradication ratesusinghigh dose ranitidine
plusamoxycillinandmetronidazolemaybesimilartothatoflowdoseomeprazoleincombination
with the same antibiotics oromeprazole with clarithromycin. Overall eradication rates were low
due to a high incidence of metronidazole resistance but were higher in metronidazole-sensitive
patients. Evenhighdose ranitidine withtwoantibiotics achieves a relatively loweradication rate.
These metronidazole-based regimens cannot be recommended in areas with a high incidence of
metronidazole resistance.
INTRODUCTION
Helicobacter pylori infection is found in most
patients suffering fromchronic active gastritis or
peptic ulceration.' Eradication of H pylori
preventsrelapsesofduodenalulcer'"2andprobably
lessens the risk of ulcer complications.36
The optimal therapeutic regimen for eradicating
Hpylori is notyetdetermined. Numerous studies
have evaluatedthecombination ofaprotonpump
inhibitor, omeprazole, with a single or double
antibiotic regimen such as amoxycillin or
clarithromycin, reporting eradication rates of
around 80O%.-9 In contrast, fewer studies have
evaluated the role of histamine-2 receptor
antagonists when combined with antibiotics.
Hentschel et al'° found that ranitidine in
combination withamoxycillinplusmetronidazole
produced an eradication rate of 89%. Ranitidine
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combined with triple therapy (bismuth,
metronidazole and tetracycline) produced an
eradication rate of 84%.1" Thus ranitidine in
combination with antibiotics may be as effective
as omeprazole plus antibiotics in the eradication
of H pylori. However few randomised studies
have compared ranitidine and antibiotics with
omeprazole and antibiotics in the eradication of
Hpylori.
Theaimsofourstudyweretoevaluatetheefficacy
ofHpylorieradicationusingranitidinecompared
to omeprazole when they are combined with
antibiotics. Theantibioticsusedwereamoxycillin
and metronidazole to produce a triple therapy
regimen without bismuth, as there is some
evidence that the addition of bismuth is not
necessary in achieving high eradication rates
with this type of triple therapy.'0 These two
regimens were compared to a control regimen of
omeprazole alone andtheregimen ofomeprazole
plus clarithromycin which has been associated
with high eradication rates.
METHODS
The study was approved by the Research Ethical
Committee of the Queen's University of Belfast
and written informed consent was obtained from
all patients.
80 dyspeptic patients who underwent upper
gastrointestinal endoscopy and were found to
have H pylori infection were studied. Patients
were excluded ifthey were allergic to any ofthe
study medication, pregnant or liable to become
pregnant, lactating, had recent gastrointestinal
haemorrhage, severe disease ofany otherkind or
had taken antibiotics in the month before entry.
The presence ofHpylori infection was assessed
by endoscopy and antral biopsies were taken for
histology and culture; rapid urease (CLO) test
and the 13C-urea breath test (UBT) were also
performed. Hpyloriinfection wasconfirmed ifat
least two of the tests were positive. Two antral
biopsiesweretakenforhistology,andthepresence
ofHpylori identified using a Giemsa stain. Two
antral biopsies were taken for culture using non-
selective medium of Columbia-based agar and
selective medium (Dent's medium), incubated in
micro-aerophilic conditions at 37°C for up to 10
days; then checked for metronidazole resistance
inColumbiablood-agarwith5mcgmetronidazole
disc incubated for 72 hours. One antral biopsy
wastakenfortheCLOtest(DeltaWest,Australia).
The 13C-ureabreathtestwasperformedaccording
to the European 13C-urea breath test protocol
and assessed by the Bureau of Stable Isotope
Analysis Ltd., England. A positive result was
taken as excess deltal3 C02 excretion > 5 per ml,
standard delta notation.'2
The patients were randomised in an investigator
blind manner to a two-week regime of (1)
omeprazole 20 mg daily, amoxycillin 500 mg tid
and metronidazole 400 mg tid (OAM); (2)
ranitidine 600mgbd, amoxycillin 500mgtid and
metronidazole400mgtid(RAM); (3)omeprazole
20 mg daily andplacebo (OP); or (4) omeprazole
20 mg daily andclarithromycin 500 mg tid (OC).
Repeat endoscopy for histology and culture and
13 C-UBT were undertaken 4 weeks after
completion of therapy. Eradication of H pylori
was considered successful if all three tests were
negative.
Compliance was assessedby return tabletcounts.
Side-effect profile was determined by visits at
two and six weeks after commencement of
treatment, and patients were asked to contact the
investigators ifthey had side-effects. Symptoms
were assessed before treatment and four weeks
after completing the treatment and graded by a
scoring system. Patients were questioned in a
standardised manner about five predefined
symptoms: epigastric pain, nausea or vomiting,
heartburn, postprandial discomfort or
regurgitation. The presence of each symptom
was scored as: 0-absent; 1 - recalled on direct
questioning; 2-presentbutnotimpairingactivities;
3-interfering with daily work and life. Frequency
ofsymptoms was scored as: 1-one day or less per
week; 2-several times each week; 3-daily. The
scores were added for each patient giving a
possible score ranging from 0 to 30.
The Chi-square test was used to compare the
eradication rates between treatments; a P value
of less than 0.05 was considered significant.
RESULTS
80 patients with H pylori infection entered the
study. Theirdemographic andclinical details are
summarised in Table 1. All four groups had
similardemographic andclinical characteristics.
Some of the patients had become asymptomatic
at the time of the initial endoscopy.
Sideeffects occurred in two(10%o) ofthepatients
in the OAM group. On complained ofnausea and
rash and withdrew from the study, and another
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TABLE I
Patient demographic and clinical characteristics
Omeprazole Ranitidine Omeprazole Omeprazole
Amoxycillin Amoxycillin Placebo Clarithromycin
Metronidazole Metronidazole (n=20) (n=20)
(n=20) (n=20)
Mean age (range) (y) 40 (18-75) 50 (18-65) 52 (26-82) 49 (28-75)
Men/women (n) 8/12 13/7 7/3 15/5
Diagnosis (n):
Duodenal ulcer disease 14 14 17 12
Oesophagitis 3 1 3 5
Gastric ulcer 1 0 0 0
Normal 3 4 3 7
Median symptom score 12 (0-23) 14 (0-22) 10 (0-22) 15 (0-30)
(range)
Smoker (n)(%) 4/7 (57%) 5/10 (50%) 3/12 (25%) 3/9 (33%)
Alcolol use (n) (%) 3/7 (43%) 7/9 (78%) 9/12 (75%) 7/9 (78%)
had diarrhoea but continued with the study. Two
(10%) of the patients in the RAM group
complained of nausea and vomiting and they
both withdrew from the study. Two (10%) ofthe
patients intheOPgroupcomplainedofdiarrhoea,
one of whom withdrew from the study. Three
(15%)ofthepatients intheOCgroupcomplained
of diarrhoea (one) and vomiting (two); they all
withdrew fromthestudy. Intotal, 11% ofpatients
suffered from side-effects and of these 9%
withdrew from the study as a result.
Compliance was good in all the groups (>90%
consumption of the delivered study medication)
with no significant differences between them
except for two patients who withdrew from the
study because of poor compliance in the OC
group. Compliance was 97% (range 86 - 100;
n=12) in the OAM group; 94% (74 - 100; n=12)
in the RAM group; 95% (72 - 100; n=13) in the
OP group; 92% (72 - 100; n=8) in the OC group.
Hpyloriresistancetometronidazole wasassessed.
Themetronidazole resistance was 50% (n =7/14)
in the OAM group; 73% (11/15) in the RAM
group; 60% (9/15) intheOPgroup;47% (7/15) in
theOCgroup. Therewasnosignificantdifference
in the metronidazole resistance between the
groups. Theoverallmetronidazoleresistancewas
58%.
The eradication of H pylori with the different
regimens are summarised in Table II. The
evaluablepatientgroup includes thepatients who
completed the study and the intention-to-treat
group includes all patients who participated in
thestudy. Thestatistical results werethesamefor
both evaluable and the intention to treat groups.
The eradication rates with the regimens which
included antibiotics were significantly higher
than that for omeprazole alone (P<0.005). There
were no significant differences in the eradication
rates between the regimens which included
antibiotics. In patients who had metronidazole
sensitive H pylori, the eradication rates were
71% (5 out of7) in the OAM group and 100% (3
out of 3) in the RAM group.
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TABLE II
Hpylori eradication rates with the different
regimens
Treatment Evaluable Intention to
(n; %) treat (n; %)
Omeprazole
Amoxycillin 6/19 (32%) 6/20 (30%)
Metronidazole
Ranitidine
Amoxycillin 8/18 (44%) 8/20 (40%)
Metronidazole
Omeprazole 0/19 (0%) 0/20 (0%)
Placebo
Clarithromycin 4/15 (27%) 4/20 (20%)
P,0.005forallregimenswithantibiotics versus omeprazole/
placebo.
No significant differences between regimens which
included antibiotics.
DISCUSSION
This study utilised the optimal design for an H
pylori eradication study which is a randomised,
investigator-blind, controlled design. We were
stringent in our definition of eradication as we
usedthreetestmethods-histology, culture, 13C-
urea breath test. H pylori was considered
eradicated if all three tests were unable to detect
it. In contrast, the recommendations regarding
the definition of eradication relies on only two
test methods'3 and some published studies only
use one method.8 14 In addition to an efficacy
analysis, we have also analysed our data on an
intention-to-treat basis to avoid over-estimating
the expected success oftreatment used in routine
clinical practice. This aspect has been neglected
in many previous studies.7 Ourconclusions were
the same regardless of the method of analysis.
At present it is uncertain which factor is more
important for antimicrobial therapies using
omeprazole-pH or antimicrobial activity.
Omeprazole has intrinsic in vitro antimicrobial
activity"' 16 and may also improve the
antimicrobial action oftheco-administered acid-
sensitive antibiotics when the intragastric pH
approaches 7.17918 We found that monotherapy
with omeprazole did not eradicate H pylori,
confirmingpreviousreportsthatomeprazolealone
merely suppressesHpyloributdoes noteradicate
it.'9
The eradication rates achieved in this study were
low compared to some previous similar studies.
The eradication rates ofranitidine 1200 mg with
amoxycillin plusmetronidazole, andomeprazole
20 mg with the same antibiotics were 44% and
32% respectively. One group has found that the
combination of omeprazole 40 mg daily with
amoxycillin and metronidazole for 14 days gave
an overall eradication rate of 91% but only 47%
with metronidazole-resistant strains.20 As the
majority of our patients had metronidazole
resistance, our results are similar to this group's
eradication rates in those with metronidazole
resistance. The only previous controlled
randomised trial using ranitidine 300 mg daily in
combination withamoxycillin andmetronidazole
for 10 days achieved an eradication rate of 89%
which is comparable to that of bismuth triple
therapy.10 However their incidence of
metronidazole resistance was low (11%) which
could explain why they achieved higher
eradication rates than us. Our eradication rate
with omeprazole 20 mg daily andclarithromycin
was low at 27% compared to previous studies
which have found eradication rates of 63 to
80%.8,9,21,22 This could be explained by the low
dose ofomeprazole used in our study in contrast
to omeprazole 40 mg daily which has been used
in the other studies.
Although there may be a trend towards higher
eradication rates in the ranitidine, amoxycillin
and metronidazole group compared to
omeprazole, amoxycillin andmetronidazole(44%
versus 32%), this lacked statistical significance
because ofthe rather small sample size. However
astudy with the powerto show clearly that a 12%
difference wastrulypresentorabsentwouldhave
required a prohibitively high number of 400
subjects (power 80%).
Several other factors affectHpylori eradication.
Compliance is important as eradication is low
withpoorcompliance.23'24Thecompliance ofour
patients was good, ranging from 92 to 97% and it
would therefore seem unlikely that this factor
would account for the low eradication rates in
this study. Metronidazole resistance is associated
with a marked reduction in eradication rates. We
found an unexpectedly high prevalence of
metronidazole resistance (58%) in this group of
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patients. Incomparison, theoverallprevalence of
metronidazole resistance in Europe is 28% with
figures ranging from 7 to 49%.25 This is the most
likely explanation for the low eradication rates
achieved with our regimens of metronidazole
with amoxycillin and ranitidine or omeprazole.
The reasons for the high prevalence of
metronidazole resistance are uncertain. It could
be speculated that there is a high usage of
metronidazole in this community. Eradication
rates increase with the total daily dose of
omeprazole in combination with amoxycillin7
and it may be that the low dose of omeprazole
used in our study could have influenced the low
eradication rates. The reason we used a low dose
of omeprazole was to try to achieve comparable
acid suppression with high dose ranitidine.
The frequency ofside-effects found in this study
(11%) is lower than that of triple therapy which
includes bismuth, where the overall frequency of
side-effects is 32%.7 Our results are more
comparable to the reported frequency of side-
effects with omeprazole plus amoxycillin which
is 11%. Howeverthe side-effects associated with
our regimens appear to be more severe than
bismuth triple therapy or omeprazole plus
amoxycillin, as 9% withdrew from our study in
consequence of side-effects compared to about
4% and 2% for the latter two regimens.7
Using the doses outlined in our study, a two-
week regimen of omeprazole 20 mg daily plus
amoxycillin and metronidazole would have cost
£23.79 and ranitidine 1200 mg daily plus
amoxycillin and metronidazole £56.25 (prices
from British National Formulary, number 28,
1994). Thus using high dose ranitidine plus
amoxycillin and metronidazole to eradicate H
pylori does not give any definite cost/benefit
advantage compared to low dose omeprazole
with the same antibiotics. The most expensive
regimen in this study was omeprazole with
clarithromycin which cost £73.26.
In conclusion, H pylori eradication rates using
high dose ranitidine plus amoxycillin and
metronidazole may be similar to that of
omeprazole in combination with the same
antibiotics or clarithromycin. Eradication rates
were probably low due to a high incidence of
metronidazole resistance. The eradication rate
was higher in metronidazole sensitive patients.
Priortousing metronidazole-based regimens, the
local metronidazole resistance rates should be
determined to ensure that efficacy is not
compromised. Even ifranitidineplusamoxycillin
and metronidazole had higher eradication rates
than omeprazole with the same antibiotics (12%
difference) undetected by the small sample size,
the former regimen would still not have been as
cost effective as the latter, and would have
involved taking a larger number of tablets.
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